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OBJECTIVE — Activation of peroxisome proliferator–activated receptor (PPAR)- signaling
inﬂuences metabolic proﬁles and the propensity toward inﬂammation. Small-molecule stimu-
lationofPPARisinvestigatedforsecondarypreventionofcardiovasculardisease.Thecommon
PPAR Pro12Ala variant has functional and prognostic consequences. A protective effect of the
12Ala-allele carriership on diabetes and myocardial infarction in healthy populations has been
suggested. The relevance of this pathway also needs exploration in patients with manifest vas-
cular disease. We investigated the effects of carriership of the Pro12Ala variant on angiographic
and cardiovascular event outcomes in male patients with symptomatic coronary artery disease
(CAD).
RESEARCH DESIGN AND METHODS — The Regression Growth Evaluation Statin
Study (REGRESS) cohort was genotyped for the Pro12Ala variant (rs1801282). Ten-year fol-
low-up was derived from nation-wide registries, and risks were estimated using proportional
hazards. Quantitative coronary angiography measurements were obtained and relations with
genotype estimated using a generalized linear model.
RESULTS — Genotypes ascertained (n  679) comprised 540 (80%) Pro/Pro, 126 (19%)
Pro/Ala, and 13 (2%) Ala/Ala subjects. The 12Ala allele was associated with less extensive focal
(P  0.001) and diffuse (P  0.002) atherosclerosis and lower 10-year cardiovascular risk.
Hazard ratios were 0.10 (95% CI 0.01–0.70, P  0.02) for ischemic heart disease and 0.24
(0.08–0.74, P  0.013) for vascular death, per each added copy of 12Ala, respectively.
CONCLUSIONS — Carriers of the 12Ala allele of PPAR have less widespread CAD and are
considerably protected against 10-year (cardio)vascular morbidity and mortality. These long-
termﬁndingsinpatientswithmanifestCADsupportanimportantroleofPPARindetermining
vascular risk.
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P
eroxisome proliferator–activated re-
ceptors (PPARs) are steroid hor-
mone nuclear receptors that modify
expression of several genes. The PPAR
subtype is preferentially expressed in adi-
pocytes, vascular smooth muscle cells,
endothelial cells, and macrophages (1)
and modulates various aspects of metab-
olism (lipids and glucose) and inﬂamma-
tion (adhesion molecule, chemokine, and
metalloproteinase-9 expression) (2) by
integrating environmental and (epi)ge-
netic signals. Target gene transcription
control by PPAR arises from molecular
interactions among various PPAR li-
gands,cofactors,dimeriziationwithret-
inoid X receptor, and binding to PPAR-
responsive elements on a number of
target promoter regions.
The clinical relevance of the PPAR
pathway was established ever since its
identiﬁcation as a high-afﬁnity target of
theanti-diabeticdrugsthiazolidinediones
(TZDs) (3).
ThePPARgenecarriesanonsynony-
mous C/G polymorphism (rs 1801282)
resulting in a proline to alanine substitu-
tion at codon 12 (Pro12Ala) of one of the
two (4) known PPAR transcripts,
PPAR2.Functionalconsequencesofthis
substitutionarelikelygivenitslocationin
an insulin-sensitive activation domain
(5), which is highly conservated across
species, and given the fact that proline
insertiongenerallyleadstoadisruptionof
secondary structures.
In line with the role of PPAR in glu-
cose metabolism, carriership of the ala-
nine allele at this polymorphic site
(12Ala) is consistently associated with a
lowerriskofdevelopingtype2diabetesin
variouspopulations(6–8).Moreover,the
12Ala variant has also been found to be
associated with a decreased risk for myo-
cardial infarction in the general popula-
tion (9). These ﬁndings suggest a role of
PPAR in the development of vascular
disease, either through its inﬂuence on
the occurrence of diabetes or directly on
atherosclerotic vascular disease.
Thus, PPAR represents a new target
in the secondary prevention of recurrent
atherosclerotic disease. To date, no stud-
ieshaveestablishedtheimpactofindivid-
ual variation in the PPAR gene on long-
term cardiovascular risk in patients with
manifest vascular disease. Therefore, we
investigated the impact of the gene poly-
morphism Pro12Ala on angiographic and
10-year cardiovascular outcomes and ad-
dressed the roles of inﬂammation and
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tients with ischemic heart disease (IHD).
RESEARCH DESIGN AND
METHODS— The study participants
werederivedfromtheRegressionGrowth
Evaluation Statin Study (REGRESS) an-
giographic trial cohort, which enrolled
884 male patients with symptomatic cor-
onaryarterydisease(CAD)between1989
and1993.Thetrialdesignandmainﬁnd-
ings have been reported previously
(10,11).Inbrief,theprimaryobjectivesof
this angiographic trial were to evaluate
the effects of 24 months of 40 mg prava-
statin therapy on the evolution of athero-
sclerotic lesions in male patients with
provenCAD.Allparticipantsgavewritten
informed consent, and the clinical trial
and subsequent DNA studies were ap-
proved by all seven institutional review
boards of the participating centers and
by the medical ethics committees of all
centers.
Morbidity and mortality 10-year
follow-up study
Withintheframeworkoftheoriginaltrial,
clinical outcomes were assessed at 24
months comprising fatal and nonfatal
myocardial infarction (MI), death due to
CAD, repeated coronary revasculari-
zation (coronary artery bypass graft or
percutaneous transluminal coronary an-
gioplasty), stroke, and death due to
noncoronary causes. To obtain 10-year
follow-up data of the participants, cause-
speciﬁcmortalityandhospitalizationdata
up until 1 January 2001 were extracted
from nationwide registries. All diagnoses
in these registers are coded according to
the International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation
(ICD-9 and ICD-10 for mortality and
ICD-9-CM for morbidity). The research
protocol was approved by the institu-
tional review board and ethics committee
of the coordinating center (University
Medical Center Utrecht). The linkage
process method is further described in an
online appendix at http://care.diabetes
journals.org/cgi/content/full/dc09-1819/
DC1 (see METHODS section A1).
Outcome events
In the outcome events analyses, we con-
sidered the primary causes of death and
the primary clinical diagnosis recorded
during hospitalization. The composite
end point “death due to ischemic heart
disease” consisted of all primary causes of
death within the ICD-9 codes 410–414
andICD-10codesI20–I25.“Deathdueto
ischemic heart disease or nonfatal myo-
cardialinfarction”additionallycomprised
the clinical occurrence of ICD-9-CM
codes 4100–4109. The composite end
point“deathduetovasculardisease”con-
sisted of all primary causes of death
within the ICD-9 codes 410–414, 430–
438, and 440–448 and ICD-10 codes
I20–I25, I60–I69, I70–I79, and F01.
Angiographic outcomes
Patients underwent coronary arteriogra-
phyuponenrollmentandat24monthsof
follow-up, according to a uniform previ-
ously described protocol (10). After com-
pletion of the follow-up period, all
angiogramswereanalyzedbyquantitative
coronary angiography (QCA). The fol-
lowing angiographic outcomes were
used: the average mean segment diameter
perpatient,reﬂectingtheextentofdiffuse
atherosclerosis, and the average minimal
obstruction diameter per patient, reﬂect-
ing extent of focal atherosclerosis, calcu-
lated as described previously (10). Both
the baseline and follow-up angiographic
data were used in the current analysis.
DNA analyses
Genomic DNA was extracted from blood
collected at baseline of the study accord-
ing to standard procedures and was avail-
able from 679 participants because of a
stock shortage. Genotyping of the PPAR
Pro12Ala variant (dbSNP rs1801282)
wasperformedusingamultiplexPCRand
immobilized probe-based assay (12)
(Roche Molecular Systems, Alameda,
CA).
Data analyses
Differences in baseline demographic and
clinicalcharacteristicsandconcentrations
of lipids among the three genotypes were
assessed by linear regression or Pearson’s

2analysis,aswastheassumptionofHar-
dy-Weinberg equilibrium.
The effect of the genotype on angio-
graphic outcomes mean segment diame-
ter and minimal obstruction diameter
were analyzed using linear regression. C-
reactive protein (CRP) levels were loga-
rithmically transformed for use as
covariates, because they were not nor-
mally distributed. The absolute risk in
each genotype group was estimated using
the Kaplan-Meier method. To explore the
presenceofbiasduetocompetingrisksin
the cause-speciﬁc end points, a compet-
ingriskanalysiswasperformedaccording
to the method of Fine and Gray (13). The
effect of genotype on outcome was ana-
lyzed using Cox proportional hazards.
The mode of inheritance exerting the
effects of this gene variant remains un-
known. We compared recessive, domi-
nant, and additive models and selected
the optimal model to describe the data
based on the lowest Akaike information
criterion. The additive model appeared to
meet this criteria for all cardiovascular
outcomes. Hence, the number of rare
allele (alanine) copies was entered as a
linearcovariateintothemodel.Thepro-
portional hazards assumption was as-
sessed for all end points through testing
the regression coefﬁcient of the interac-
tion between the covariate(s) and time
andwasveriﬁedvisuallybyalog-logplot.
In all instances, the assumption was
satisﬁed.
Forboththecardiovascularoutcomes
as the angiographic outcomes, the role of
possible intermediate factors or possible
bias from confounding factors was ex-
plored in multivariate analyses. These in-
cluded the components of the metabolic
syndrome and baseline CRP levels. To
take into account the randomized nature
of the ﬁrst 2 years of the follow-up
study, we veriﬁed if adjustment for ran-
domization group changed the effects
found. Throughout, a two-tailed P value
of0.05wasinterpretedasindicatingasta-
tistically signiﬁcant difference. All statis-
tical analyses were carried out by two of
theauthors(J.J.R.andA.H.Z.)usingSPSS
for Windows, release 15.0 (SPSS, Chi-
cago,IL).Allauthorshadfullaccesstothe
data and take responsibility for its integ-
rity.Allauthorshavereadandagreetothe
article as written.
RESULTS
Distribution of allele frequencies
The study population (n  679) com-
prised 540 (80%) Pro/Pro, 126 (19%)
Pro/Ala, and 13 (2%) Ala/Ala subjects, re-
spectively, meeting the Hardy-Weinberg
equilibrium assumption (P  0.094) and
closely resembling distributions reported
in other Caucasian populations (9). Base-
line characteristics according to genotype
are shown in Table 1.
Of note, the 12Ala carriers had a
lower systolic blood pressure, which
reached borderline signiﬁcance for
diastolic blood pressure. Otherwise, no
signiﬁcant differences were observed
amongthegenotypesinbaselinecoronary
heart disease risk factors including li-
poprotein proﬁle or lifestyle parameters.
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outcome events
Among the 679 patients included in the
survival analysis, 111 died during follow-
up; 53 patients died from vascular dis-
ease, and 43 deaths were caused by IHD.
The composite of nonfatal MI or death
from IHD occurred in 81 subjects. After
10 years of follow-up, carriers of the
12Ala allele had a considerably reduced
risk. For instance, risk of vascular death
was 10.0% (SE 1.4%) in Pro12/Pro12,
whereas it was 2.5% (SE 1.4%) in Pro12/
12Ala and 0% in 12Ala/12Ala carriers, as
displayedalsoinTable3.The12Alaallele
thus conferred both a reduced risk of vas-
cular death (hazard ratio [HR] 0.24 [95%
CI 0.08–0.74]), death from IHD (0.10
[0.01–0.70]), and nonfatal MI or IHD
(0.42 [0.21–0.84]). Table 3 displays
theserespectiveHRspereachaddedallele
copy of 12Ala. HRs adjusted for compo-
nents of the metabolic syndrome and
randomization group (ﬁrst 2 years of
thefollow-up)orbaselineCRPleveland
randomization group did not yield sub-
stantial changes in the effects found. In
all instances, the competing risk analy-
sis (data not displayed) did not change
the effect found.
Genotype and angiographic extent of
CAD
The possession of a 12Ala allele was asso-
ciated with a moderate increase in coro-
nary arterial diameters (Table 2) in both
the average mean segment diameter and
theaverageminimalobstructiondiameter
and in both the baseline and the 24-
month follow-up angiograms in the
study.
The coefﬁcients from multivariate
models are displayed in online appendix
Table A1. Notably, these multivariate
analyses revealed that the relations were
found both on cardiovascular and angio-
graphicendpointsgenerallycontinuedto
be signiﬁcant in models 1 and 2. In these
models, relations between established
risk factors and outcomes were generally
not signiﬁcant, presumably due to lack of
statistical power in this cohort.
CONCLUSIONS — This long-term
follow-up study in 679 CAD patients
demonstratesthesigniﬁcanceonbothan-
giographic outcome and cardiovascular
mortalityofafrequentvariantinPPAR2.
The 12Ala isotype in this group of pa-
tients was associated with less extensive
coronary atherosclerosis and better 10-
year prognosis. Although the mechanism
underlying these observations remains
unexplained,thissupportsthehypothesis
thatPPAR2,expressedpredominantlyin
adipose tissue (14), plays an important
role in the prognosis of patients with
symptomatic CAD.
First, we found that carriership of the
PPAR2 12Ala isotype, as can be found in
21% of Caucasians (9,15), is associated
with a decreased 10-year cardiovascular
mortality compared with the Pro12 iso-
type. An allele-dose effect seemed
present,notablyforIHDandvasculardis-
ease–causeddeathsandincidentmyocar-
dial infarction. To our best knowledge,
these are the ﬁrst prospective data on the
prognosticimpactofthePro12Alavariant
in patients with manifest coronary or
other vascular disease. However, this re-
lation has been addressed in the general
population. A matched nested case-
control study (9) of incident MI among
2,615 healthy men followed for 13.2
years in the Physicians’ Health Study ob-
served a protective effect of the 12Ala al-
Table 1—Baseline demographic and CAD characteristics according to the PPAR Pro12Ala
genotype
Pro/Pro Pro/Ala Ala/Ala P
Age (years) (SEM) 55.7  0.34 55.7  0.74 57.0  1.7 0.82*
BMI (kg/m
2) 25.9  0.11 26.3  0.26 25.8  0.60 0.24*
Systolic blood pressure (mmHg) 135.8  0.78 134.1  1.74 126.2  4.1 0.07*
Diastolic blood pressure (mmHg) 81.8  0.43 81.0  0.91 74.6  3.3 0.05*
Current smoking (%) 153 (28%) 34 (27%) 0 (0%) 0.08†
Ejection fraction 70.2  0.55 70.2  1.13 73.5  3.7 0.66*
NYHA functional class 0.17†
I 63 (12%) 8 (6%) 3 (23%)
II 262 (49%) 64 (50%) 8 (62%)
III 178 (33%) 39 (39%) 1 (8%)
IV 33 (6%) 6 (5%) 1 (8%)
History of hypertension (%) 160 (30%) 35 (28%) 3 (23%) 0.80†
Previous MI (%) 265 (49%) 57 (45%) 4 (31%) 0.32†
Number of vessels diseased
1 (%) 229 (43%) 55 (44%) 5 (38%)
2 (%) 185 (34%) 40 (32%) 7 (54%)
3 (%) 124 (23%) 31 (25%) 1 (8%) 0.52†
Fasting glucose (mmol/l) 5.28  0.05 5.37  0.11 5.22  0.23 0.62*
CRP (mg/l) 5.42  0.54 6.37  1.15 2.71  0.85 0.99*§
-Fibrinogen (g/l) 3.39  0.07 3.21  0.17 3.15  0.32 0.18*§
Total cholesterol (mmol/l) 6.05  0.04 6.04  0.08 5.86  0.25 0.75*
HDL (mmol/l) 0.93  0.01 0.90  0.02 1.01  0.07 0.12*
Triglycerides (mmol/l) 1.78  0.03 1.87  0.07 1.62  0.21 0.42*§
LDL (mmol/l) 4.31  0.03 4.03  0.07 4.07  0.20 0.6*
Data are means  SE unless otherwise indicated. P values were determined by *linear regression, †
2 for
cross-tabs. §P value applies to log-transformed triglycerides, CRP, and -ﬁbrinogen levels due to non-
normality . Pro, proline; Ala, alanine at codon 12 of PPAR.
Table 2—Effect of genotype (Pro12Ala) on angiographic extent of CAD: baseline and 24-
month follow-up angiographic recordings
Pro/Pro Pro/Ala Ala/Ala B* P
Angiographic end point
Baseline MOD (mm) 1.84 (0–3.78) 1.93 (0–3.75) 2.29 (1.0–3.85) 0.162 0.002
Follow-up MOD (mm) 1.76 (0–4.28) 1.90 (0–3.87) 2.15 (1.17–3.2) 0.137 0.011
Baseline MSD (mm) 2.77  0.02 2.94  0.06 2.96  0.26 0.145 0.001
Follow-up MSD (mm) 2.70  0.02 2.84  0.06 2.80  0.18 0.110 0.014
Data are means  SE or medians (minimum to maximum). MOD, median minimal obstruction diameter,
representing focal atherosclerotic changes. Medians are presented here to illustrate genotype effects because
of the skewed distribution of MOD. MSD, mean average mean segment diameter, representing diffuse
atherosclerotic changes. *Regression coefﬁcient from general linear model.
Regieli and Associates
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0.99). The ﬁnding was not replicated in a
later report of incident MI or CHD death
in two matched case-control samples of
shorter follow-up durations in 730 men
and 752 women nested within the Health
Professionals Follow-up Study and
Nurses’ Health Study, respectively (15).
In the latter report, the pooled effect of
both samples suggested an elevated risk
in presence of the 12Ala allele, reaching
borderline signiﬁcance (OR 1.30, 95% CI
1.00–1.67). Further, a case-control re-
port in 844 Han Chinese described a sig-
niﬁcantly increased risk of MI in 12Ala
allele carriers (unadjusted OR 1.83,
95%CI1.06–3.14).Onepotentialexpla-
nation for opposing ﬁndings may be
found in the existence of gene-environ-
ment interactions. Notably, the data of
Pischon et al. (15) suggest that the prog-
nosticeffectwasmodiﬁedbythepresence
of obesity.
Second,weobservedalowerextentof
focal and diffuse atherosclerosis (respec-
tively higher minimal obstruction diame-
ter and mean segment diameter)
associated with the presence of the 12Ala
allele, and an allele-dose effect seemed
present. However, no effect was detected
ontherateofprogressionofatherosclero-
sisduringthe24-monthangiographicfol-
low-up. Although possibly due to low
statistical power, in this regard, it is
tempting to speculate that vascular pro-
cesses apart from atherogenesis might ad-
ditionally explain the 10-year prognostic
effect of the PPAR variant.
So far, no other QCA data have been
reported in relation with the Pro12Ala
polymorphism. However, a study in 267
Korean subjects undergoing coronary an-
giography reported no effect of the
Pro12Ala polymorphism on the number of
vessels diseased, possibly due to low statis-
tical power or precision, as the authors
stated (16). However, presence of the Ala-
nine12isotypehasbeenconsistentlyrelated
to decreased intima-media thickness (IMT)
in622Germanindividualsbearingriskfac-
torsfordiabetes(17),154Japanesediabetes
patients(18),and161healthyCanadianab-
originals (19). This agrees with the current
QCA ﬁndings and supports effects of
PPAR on atherogenesis.
Mechanism
The mechanism mediating the protective
effectsofthe12Alaalleleasadeterminant
ofangiographicandclinicaloutcomesob-
served here remains unresolved. To dis-
close intermediate factors, we performed
several multivariate analyses.
First, given involvement of PPAR2 in
adipogenesis (14), and Pro12Ala in partic-
ular as a genetic determinant of type 2 dia-
betes (7,20), BMI (17,21,22), and blood
pressure (23), we elected to incorporate
components of the metabolic syndrome as
covariates. In the current analysis, carrier-
ship of the 12Ala allele continued to be sig-
niﬁcantly associated with a decrease of 10-
year cardiovascular outcome. This is
supported by data obtained in the general
population (9), which did not reveal any
indication of diabetes as an intermediate
factor. Hence, the metabolic syndrome or
its components appear not to account for
therelationbetweenthePro12Alapolymor-
phism and cardiovascular risk.
Second, in REGRESS, effects of the
Pro12Ala variant on cardiovascular risk
were independent of baseline CRP levels
inmultivariateanalyses.Carriersof12Ala
appeared to exhibit slightly lower mean
baseline levels of CRP and -ﬁbrinogen,
and this trend had also been observed in
otherreports(15)butwasnotstatistically
signiﬁcant. Thus, reduced inﬂammation
most likely is not the mechanism explain-
ing the effects observed.
Interestingly, it has been previously
reported that the Alanine allele deter-
mines lower lipoprotein lipase activity
with a high triglyceride–low HDL choles-
terol proﬁle, in two independent popula-
tions (n  294), both diabetic and
nondiabetic (24). However, the prognos-
tic effect of lower lipoprotein lipase activ-
ity remains unknown. Our current data
from REGRESS do not reveal such an ef-
fect of the Pro12Ala polymorphism on li-
poprotein proﬁle. Accordingly,
lipoprotein lipase activity is not likely an
explanation for the effects of Pro12Ala on
angiographic and 10-year clinical out-
comes.
Study strengths and limitations
To appreciate these ﬁndings, some as-
pects of our study merit consideration.
First, the longitudinal REGRESS study
constitutes a cohort of CAD patients
with 10 years of follow-up. The QCA
Table 3—Effect of PPAR genotype on outcome
Genotype HR perAla allele copy
Clinical end point
Pro/Pro
(n  540)
Pro/Ala
(n  126)
Ala/Ala
(n  13) Univariate model Multivariate model 1 Multivariate model 2
Death from IHD 8.2 (1.2) 0.8 (0.8) 0 0.10 (0.01–0.70) 0.10 (0.14–0.72) —
n 42 1 0
P 0.02 0.02
Death from IHD or non-fatal MI 17.6 (2.3) 7.3 (2.5) 0 0.42 (0.21–0.84) 0.46 (0.23–0.92) 0.28 (0.09–0.85)
n 73 8 0
P 0.01 0.03 0.03
Death from vascular disease 10.0 (1.4) 2.5 (1.4) 0 0.24 (0.08–0.74) 0.17 (0.04–0.67) 0.13 (0.018–0.92)
n 50 3 0
P 0.01 0.01 0.04
All-cause mortality 18.9 (1.9) 12.6 (2.9) 0 0.66 (0.41–1.07) 0.57 (0.34–0.97) 0.63 (0.34–1.18)
n 94 17 0
P 0.09 0.04 0.02
Dataare%(SE%)orhazardratio(95%CI)unlessotherwiseindicated.Ten-yearabsoluterisk(%andSE)ofcompositeoutcomeevents(Kaplan-Meierestimate)and
absolute number of cases (uncensored data) are displayed per genotype on the left. Hazard ratios (with corresponding 95% CI and P value) per each additional
Alanine allele copy are displayed on the right. Multivariate model 1 controls for randomization group, BMI, fasting blood glucose, triglyceride and HDL cholesterol
levels, systolic and diastolic blood pressure, self-reported hypertension, antihypertensive drug use, and antidiabetic drug use. Multivariate model 2 controls for
randomization group and ln(CRP). (—), Unable to estimate due to empty cell.
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to observe effects on the extent of athero-
sclerosis. A second consideration is that
the data originate from a randomized trial
in which assessment of the beneﬁts of
pravastatintreatmentwastheprimaryob-
jective. Because the study medication
takenduring2yearsofthefollow-uptime
was allocated at random, i.e., irrespective
of genotype, this will not have affected
ourﬁndings.Third,ourfollow-updataset
was not complete for all patients: 3 and
16% of patients could not be uniquely
identiﬁed in the mortality and hospital
registries, respectively. Because these pa-
tients were right-censored at lost-to-
follow-up time, again it seems unlikely
that this would have affected the primary
outcome of the current study. We elected
tocalculateactuarialsurvivalacrossgeno-
types,incontrasttothematched(9,15)or
unmatched(25)case-controldesign.Sur-
vival analysis enabled us to efﬁciently
study all available information, including
that of censored participants. Fourth,
with the current data, we did not identify
the underlying mechanisms (putatively,
the metabolic syndrome and inﬂamma-
tory state). The lack of information on the
occurrence of the metabolic syndrome or
inﬂammatory parameters over time limits
deﬁnitive conclusions in this respect. Fi-
nally,animportantissueisthattheresults
in this study were obtained in a cohort of
male patients with established CAD, and
further research is needed to demonstrate
whether the results of our study also ap-
ply to women. Nevertheless, the current
ﬁndings from REGRESS are the ﬁrst long-
term data on hard clinical end points col-
lected prospectively and add to the
understanding on the role of PPAR in
cardiovascular disease.
In conclusion, among symptomatic
CAD patients, carriership of the 12Ala
variant of PPAR is associated with less
extensive atherosclerotic disease and
appearstoprotectagainstrecurrentvas-
cular disease and vascular mortality, as
observed in a long-term follow-up
study. These long-term ﬁndings in pa-
tients with manifest CAD support an
importantroleofPPAR indetermining
vascular risk.
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